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Abstract
Background: Accurately indentifying heart failure (HF) patients from administrative claims data is
useful for both research and quality of care efforts. Yet, there are few comparisons of the various
claims data criteria (also known as claims signatures) for identifying HF patients. We compared
various HF claim signatures to assess their relative accuracy.
Methods: In this retrospective study, we identified 4174 patients who received care from a large
health system in southeast Michigan and who had ≥1 HF encounter between January 1, 2004 and
December 31, 2005. Four hundred patients were chosen at random and a detailed chart review
was performed to assess which met the Framingham HF criteria. The sample was divided into 300
subjects for derivation and 100 subjects for validation. Sensitivity, specificity,, and area under the
curve (AUC) were determined for the various claim signatures. The criteria with the highest AUC
were retested in the validation set.
Results: Of the 400 patients sampled, 65% met Framingham HF criteria, and 56% had at least one
B-type Natriuretic Peptide (BNP) measurement. There was substantial variation between claims
signatures in terms of sensitivity (range 15%-77%) and specificity (range 69%-100%). The best
performing criteria in the derivation set was if patients met any one of the following: ≥2 HF
encounters, any hospital discharge diagnosis of HF, or a BNP ≥200 pg/ml. These criteria showed a
sensitivity of 76%, specificity of 75%, and AUC of 0.754 for meeting the Framingham HF criteria.
This claims signature performed similarly in the validation set.
Conclusion: Claim signatures for HF vary greatly in their relative sensitivity and specificity. These
findings may facilitate efforts to identify HF patients for research and quality improvement efforts.
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Background
Heart failure (HF) is a major public health problem in the
United States. Approximately 5 million patients have HF,
and over 550,000 patients are diagnosed with HF for the
first time each year [1]. It is the fifth ranking cause for hos-
pitalization overall, and a leading cause for hospitaliza-
tion in the elderly [1].
Many quality initiatives and clinical research efforts rely
on administrative claims data to identify patients with HF.
Most often this involves identifying individuals coded
with a diagnosis of HF according to International Classifi-
cation of Diseases 9 (ICD9) codes. While claims data are
widely available, their utility is limited by the fact that
encounters coded as HF may not reflect accepted epidemi-
ologic criteria. To try to improve the utility of administra-
tive data, various claim signatures using combinations of
specific codes, such as multiple encounters or particular
encounter types (e.g., hospitalizations) have been uti-
lized.
Unfortunately, even by restricting code types (i.e. inpa-
tient vs. outpatient, primary vs. secondary) or using com-
binations of codes identification of HF patients using
administrative data is imperfect. For example, one study at
our institution showed that more than a third of patients
identified as having HF by administrative codes did not
satisfy Framingham HF criteria [2]. On the other hand,
claim signatures with greater specificity, such as those
requiring a primary hospital discharge diagnosis of HF,
have been shown to result in samples in which >90% of
subjects meet the Framingham HF definition [3]. How-
ever, this latter approach is likely at great cost to sensitiv-
ity, thereby under-identifying patients with known HF.
Perhaps more problematic is the paucity of data compar-
ing such criteria in order to provide some estimate of their
performance. In addition to claims data, many health sys-
tems have access to electronic laboratory results which can
be queried. Included in these laboratory data may be BNP
measurement. These levels have been shown to be helpful
in differentiating HF from other causes of dyspnea [4].
Therefore, augmenting claims data with laboratory data,
specifically BNP levels, may be useful in identifying HF
patients from electronic data sources.
In this study, we sought to compare the relative accuracy
of various claim signatures for HF using both administra-
tive claims data and laboratory BNP levels by testing them
against a widely used HF criterion.
Methods
Study Population and Setting
This study was approved by the Institutional Review
Board at Henry Ford Health System. The study was also in
compliance with the health system's Health Insurance
Portability and Accountability Act policy. Patients were
both members of a large, health maintenance organiza-
tion (HMO) in southeast Michigan and received their care
from a large, multi-specialty medical group. To be
included in the cohort, patients had to be age ≥18 years
and have at least one encounter code for HF (ICD9 codes
428.xx, 398.91, 402.01, 402.11, or 402.91) between Jan-
uary 1, 2004 and December 31, 2005 (excluding all emer-
gency department encounters). In order to minimize
misclassification of patients as having heart failure we
excluded patients with a diagnosis of end-stage renal dis-
ease or chronic obstructive pulmonary disease with ster-
oid use as these conditions can manifest symptoms
confused with heart failure. We identified end stage renal
disease by encounter ICD-9 codes (585, 586, V42.0,
996.81) or procedure codes (M0916, M0920, M0932,
M0936, M0937, M0945, M0974, M0978, M0982,
W6800, X3732, 36800, 3681A, 3681B, 3681C, 36810,
36815, 3683C, 3683E, 36833, 90925, 90935, 90937,
90941, 90942, 90943, 90944, 90945, 90947, 90951,
90952, 90953, 90954, 90955, 90956, 90957, 90958,
90966, 90967, 90969, 90976, 90977, 90978, 90979,
90982, 90983, 90984, 90985, 90989, 9099C, 9099D,
9099E, 9099F, 90993, 90999, 90921, 90919, A4726,
A4656, 90922, A4722, 50360, 50365, 50370, 50380).
Chronic obstructive pulmonary disease was identified by
encounter ICD-9 code (490, 491, 492, 493, 494, 495, 496,
500, 501, 502, 503, 504, or 505) and oral steroid use (i.e.,
a pharmacy claim for a fill of prednisone or NDA category
P5A) over the time period from January 1, 2004 through
December 31, 2005. We identified 4,174 patients from
which we randomly selected a sample of 400 patients to
have a detailed medical chart review.
Endpoint Assessment
A physician reviewed each medical chart in detail and doc-
umented the presence or absence of major and minor
Framingham HF criteria [5]. Patients were classified as
having satisfied the Framingham definition for HF if they
met either two major criteria or one major and two minor
criteria. Patients were also categorized according to 18 dif-
ferent case-definitions using claims and laboratory data.
These latter definitions used various combinations of HF
coded encounters (e.g., ambulatory setting, hospital set-
ting, primary diagnosis, secondary diagnoses, but
excluded any emergency department encounters) and
BNP levels. For the purpose of this study we define a claims
signature as any definition using a combination of these
data queried electronically.
Statistical Analysis
The cohort of 400 patients was divided into 300 subjects
for derivation testing, and 100 subjects were used to vali-
date the top performing claims signature definitions. The
Framingham HF definition was chosen as the comparatorBMC Health Services Research 2009, 9:237 http://www.biomedcentral.com/1472-6963/9/237
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criteria as it has been widely used in previous studies. Sen-
sitivity, specificity, likelihood ratios, and area under the
curve (AUC) were determined for each claim signature as
compared to classification using Framingham criteria. The
claims signatures with the highest AUC were retested in
the validation set. All calculations were performed using
SAS 9.1.3 (SAS Institute Inc.)
Results
A total of 4,174 patients had at least one encounter code
for HF. From this population, a sample of 400 patients
was randomly chosen for further examination. This group
of 400 patients was further divided into a derivation set (n
= 300) and a validation set (n = 100). The characteristics
of subjects in the derivation set, validation set, and
remaining patient parent population are shown in Table
1. These characteristics were similar across groups except
for the prevalence of coronary disease which was higher in
unselected patients compared to the randomly selected
study cohort (20% vs. 14% vs. 15%, p = 0.012). Overall,
65% of subjects in the study sample met the Framingham
definition of HF. Fifty seven percent of the total cohort
and 56% of the study sample had at least one BNP meas-
urement.
Calculated sensitivity, specificity, and area under curve
(AUC) for each claims signature relative to the Framing-
ham HF definition is shown in Table 2. The best perform-
ing case-definition was the following combination: ≥2
outpatient encounters for HF, any hospital discharge diag-
nosis of HF, or any single BNP ≥200 pg/ml. These criteria
had a sensitivity of 76.3%, specificity of 74.5%, positive
likelihood ratio of 3.0, negative likelihood ratio of 0.32,
and an AUC of 0.754 for meeting the Framingham HF cri-
teria. When retested in the validation patient sample, this
definition performed similarly with sensitivity of 78%, a
specificity of 69%, and an AUC of 0.735. Since this valida-
tion AUC was lower than three other definitions from the
derivation set, we also retested these three definitions in
the validation set (Table 3). The obtained AUCs were
0.725, 0.730 and 0.711 respectively, consistent with the
relative performance of the derivation set.
As electronically searchable laboratory data may not be
available in other health systems, we examined the best
performing definition using only claims data. The best
performing of these criteria was as follows: ≥2 HF ambu-
latory encounters or any hospital discharge (definition #2
in Table 2). This combined definition had a sensitivity of
69%, a specificity of 81%, and an AUC of 0.748 when
compared with the Framingham HF criteria, and per-
formed similarly in validation (see Table 3). When com-
paring this definition to the best one employing BNP
measures, there was only a modest increase in the AUC
Table 1: Characteristics of patients with at least one encounter for heart failure between January 1, 2004 and December 31, 2005 
stratified by their participation in the study derivation and validation sets.
Variable Total Population
(n = 4,174)
Derivation sample
(n = 300)
Validation sample 
(n = 100)
Unselected patients 
(n = 3,774)
P-value*
Age (years) -- mean ± SD 67 ± 14 67 ± 14 68 ± 14 67 ± 14 0.47
Male -- no.(%) 2011 (48%) 155 (52%) 46 (46%) 1810 (48%) 0.42
White -- no. (%) 2615 (63%) 61% 59% 63% 0.12
Hypertension -- no. (%) 3384 (81%) 244 (81%) 77 (77%) 3063 (81%) 0.57
Diabetes -- no. (%) 1409 (34%) 104 (35%) 31 (31%) 1274 (34%) 0.80
Chronic obstructive 
pulmonary disease - no. (%)
600 (14%) 46 (15%) 12 (12%) 542 (14%) 0.71
Coronary Atherosclerosis - 
no. (%)
829 (20%) 42 (14%) 15 (15%) 772 (20%) 0.012
≥1 BNP measurement during 
the study period - no. (%)
2374 (57%) 170 (57%) 53 (53%) 2151 (57%) 0.73
Maximum BNP level - median 
(interquartile range)
198
(88-494)
192
(84-500)
144
(90-379)
201
(89-500)
0.634
SD denotes standard deviation
*P-value for the comparison across patients in the derivation set, patients in the validation set, and patients not used in the analysis.BMC Health Services Research 2009, 9:237 http://www.biomedcentral.com/1472-6963/9/237
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Table 2: Performance of various definitions for heart failure in derivation set (n = 300)*
# Heart failure criteria based on claims and laboratory data Sensitivity Specificity AUC
1 ≥2 heart failure encounters OR any hospital discharge diagnosis of heart failure OR BNP ≥ 200 pg/ml 76.29 74.53 0.754
2 ≥2 heart failure encounters OR any hospital discharge diagnosis of heart failure 68.56 81.13 0.748
3 ≥2 heart failure encounters OR BNP ≥ 200 pg/ml 69.59 79.25 0.744
4 ≥2 heart failure encounters OR any hospital discharge diagnosis of heart failure OR BNP ≥ 500 pg/ml 69.59 78.3 0.739
5 ≥2 heart failure encounters OR primary hospital discharge diagnosis of heart failure 60.31 85.85 0.729
6 ≥2 heart failure encounters OR BNP ≥ 100 pg/ml 76.29 68.87 0.726
7 ≥2 heart failure encounters 58.76 85.85 0.723
8 ≥2 heart failure encounters AND ≥ 1 BNP ≥ 50 pg/ml OR any hospital discharge diagnosis of heart failure 
OR ≥ 1 BNP ≥ 200 pg/ml
59.28 81.13 0.702
9 ≥2 heart failure encounters AND ≥ 1 BNP ≥ 50 pg/ml OR primary hospital discharge diagnosis of heart 
failure OR ≥ 1 BNP ≥ 500 pg/ml
38.66 90.57 0.646
10 Any hospital discharge diagnosis of heart failure OR BNP ≥ 500 pg/ml 40.72 87.74 0.642
11 Any hospital discharge diagnosis of heart failure 35.05 91.51 0.633
12 BNP ≥ 100 pg/ml 48.97 76.42 0.627
13 BNP ≥ 200 pg/ml 36.08 87.74 0.619
14 Primary hospital discharge diagnosis of heart failure OR BNP ≥ 500 pg/ml 24.23 95.28 0.598
15 BNP ≥ 500 pg/ml 20.1 95.28 0.577
16 Any primary hospital discharge diagnosis of heart failure 14.95 100 0.575
*Calculated sensitivity, specificity, and area under curve for each claim signature is compared to the Framingham definition of heart failure (i.e., 
meeting either two major criteria or one major and two minor criteria).
Table 3: Replication of definitions #1 - #4 in validation set of patients (n = 100)*
# Heart failure criteria based on claims and laboratory data Sensitivity (%) Specificity (%) AUC
1 ≥2 heart failure encounters OR any hospital discharge diagnosis of heart failure OR ≥ 1 BNP level 
≥ 200 pg/ml
78.46 68.57 0.735
2 ≥2 heart failure encounters OR any hospital discharge diagnosis of heart failure 70.77 74.29 0.725
3 ≥2 heart failure encounters OR ≥ 1 BNP level ≥ 200 pg/ml 63.08 82.86 0.730
4 ≥2 heart failure encounters OR any hospital discharge diagnosis of heart failure OR ≥ 1 BNP 
≥ 500 pg/ml
70.77 71.43 0.711
*Calculated sensitivity, specificity, and area under curve for each claim signature is compared to the Framingham definition of heart failure (i.e., 
meeting either two major criteria or one major and two minor criteria).BMC Health Services Research 2009, 9:237 http://www.biomedcentral.com/1472-6963/9/237
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between the two criteria (0.748 vs. 0.754, respectively);
however, this difference was statistically significant (P
value = 0.02).
Discussion
Administrative data have inherent limitations in terms of
accuracy but may be a valuable resource because of their
wide availability and the potentially large number of sub-
jects that can be identified through their use. To our
knowledge, this is the first study to formally compare dif-
ferent criteria for HF using electronic data sources. In so
doing, we found that our best performing criteria had an
AUC of 0.754, and maintained a reasonable sensitivity
and specificity of 76.3% and 74.5%. We realize that the
tradeoff between sensitivity and specificity depends on
the purpose for which these data are to be used. For exam-
ple, projects focusing on the quality of HF care may want
to be confident subjects actually have HF and thus may
select the highest specificity criteria, while another project
with the objective of identifying the probable size of the
affected population may opt for a criterion with high sen-
sitivity. Therefore, we anticipate that the range of claims
signatures that we present may be helpful to broad variety
of users, such as researchers, chronic care managers, and
providers.
While there appears to be a paucity of studies assessing the
accuracy of claims signatures of heart failure, our data fit
well into the context of existing data. As pointed out
above, a hospital discharge with primary diagnosis of HF
has been shown to be quite specific for heart failure [3].
Our data supported this, showing 100% specificity, but
also added further insight by revealing that the associated
sensitivity was extremely low at only 15%. A previous
study from our institution using the claim signature of
two outpatient encounters or any hospital discharge for
HF found that the resulting cohort failed to meet Framing-
ham HF criteria [2]. In contrast, in our data set using the
same criteria, 87% of subjects met Framingham definition
for HF. This could suggest that physician diagnosis and
coding for heart failure has improved over time since the
prior analysis was from 1989-1999 and ours from 2004-
2005. Alternatively this could be due to the mistaken
inclusion of more patients with renal disease in the
former study, since its criteria included cardiovascular
codes with chronic kidney disease. This suggests that some
patients may have been coded (using a single ICD9 code)
as having both renal failure and HF but upon closer scru-
tiny may not have met objective criteria for HF. There is
one previous study assessing the under-diagnosis and/or
under-coding of HF among patients with coronary disease
[6]. While HF is likely under recognized in the commu-
nity, our study did not address this important issue.
Rather it was focused on another essential task, identify-
ing likely HF patients from among those so coded, since
many do not meet standard criteria.
These data have several additional limitations that should
be noted. First, our study was performed at a single health
system, and therefore our results may differ from other
systems. However, our covered patient population is gen-
erally reflective of the population of southeast Michigan,
and it is demographically diverse in terms of race-ethnic-
ity and socioeconomic status. Second, we initially selected
patients who had at least one HF encounter. While this
assuredly increased the prevalence of true HF cases in the
sample (i.e., 65% of the study sample met Framingham
criteria for HF), we felt this was the most practical
approach since sampling from the total population
(~150,000 covered lives) would have likely resulted in a
very small proportion of HF cases and therefore would
have required samples sizes beyond the scope of the cur-
rent project to discern differences between claim signa-
tures. Because of our approach, we could not assess for
physician under-diagnosis of HF, as has been addressed
elsewhere [6]. Still, this should be considered as a limita-
tion of our approach, specifically that patients who did
not meet Framingham criteria may still have actual HF
and by selecting subjects who had at least one code for HF
this could have been amplified. As such, our claims signa-
tures are unlikely to be able to rule out the existence of HF.
Yet HF patients without at least one diagnosis code for HF
are unlikely to be reliably identified through other admin-
istrative data (i.e., other diagnostic codes or laboratory
values) and therefore would be an impractical population
for whom to develop a claims signature. Another limita-
tion is that there was a difference in the prevalence of cor-
onary disease between the study cohort and the broader
source population. This selection bias could in theory
effect the results, however the direction and magnitude of
this bias is unknown. Finally, there is no universally rec-
ognized 'best' definition for HF [7], and several other val-
idated criteria exist such as the Boston [8], NHANES [9]
and Minnesota criteria [7]. While some of these may per-
form better than the Framingham criteria, the latter con-
tinue to be widely recognized and utilized [7,10,11].
Utilizing a different set of HF criteria could have resulted
in different absolute estimates of sensitivity and specifi-
city.
Conclusions
In summary, we observed considerable variation in the
sensitivity and specificity of the various criteria for heart
failure using electronic data sources. However, we did
identify a best performing combination of diagnoses and
laboratory results which showed consistent performance
in validation. We hope that these findings may facilitate
efforts to identify HF patients for research and qualityPublish with BioMed Central    and   every 
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improvement efforts, or at minimum encourage others to
consider this variation when deciding on criteria to iden-
tify HF patients in their own patient population.
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